Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Opdualag (nivolumab and relatlimab) is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.
• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• The combination of nivolumab/relatlimab showed no significant difference in progression-free survival (PFS) and overall response rate (ORR) compared to ipilimumab/nivolumab (PFS: HR = 0.99 [95% CI 0.75-1.31], ORR: RR = 0.99 [95% CI 0.78-1.27]).
• PD-(L)1/BRAF/MEK inhibitors triplet combinations demonstrated superior effectiveness in PFS (HR = 0.56 [95% CI 0.37-0.84]) and ORR (RR = 3.07 [95% CI 1.61-5.85]) compared to ipilimumab/nivolumab.
• Nivolumab/relatlimab was ranked third in efficacy among the regimens compared, following nivolumab 1 mg/kg plus ipilimumab 3 mg/kg and nivolumab 3 mg/kg plus ipilimumab 1 mg/kg.
• Relatlimab/nivolumab demonstrated a trend towards a lower risk of grade ≥3 treatment-related adverse events (TRAEs) compared to ipilimumab/nivolumab (RR = 0.71 [95% CI 0.30-1.67]).
• Ipilimumab/nivolumab had the highest risk of developing grade ≥3 TRAEs, while relatlimab/nivolumab trended towards a better safety profile compared to ipilimumab/nivolumab, although specific comparative data were not provided for three other regimens.
• There is no population types or subgroups information available in the reviewed studies.